Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Gains from Investment Securities (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Gains from Investment Securities data on record, last reported at $2.9 million in Q4 2025.

  • For Q4 2025, Gains from Investment Securities rose 471.37% year-over-year to $2.9 million; the TTM value through Dec 2025 reached $2.9 million, up 514.04%, while the annual FY2025 figure was $2.9 million, 514.04% up from the prior year.
  • Gains from Investment Securities reached $2.9 million in Q4 2025 per APLS's latest filing, down from $6.4 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $19.7 million in Q3 2022 and bottomed at -$26.0 million in Q2 2023.
  • Average Gains from Investment Securities over 5 years is $798663.2, with a median of $510632.5 recorded in 2024.
  • Peak YoY movement for Gains from Investment Securities: plummeted 21018.7% in 2023, then soared 2966.67% in 2025.
  • A 5-year view of Gains from Investment Securities shows it stood at $8.8 million in 2021, then plummeted by 80.43% to $1.7 million in 2022, then soared by 80.14% to $3.1 million in 2023, then tumbled by 125.27% to -$786000.0 in 2024, then skyrocketed by 471.37% to $2.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $2.9 million in Q4 2025, $6.4 million in Q3 2025, and $743265.0 in Q2 2025.